image-150-64c8cd514b55a.webp

image-151-64c8cd518a917.webp

group-1000002623-64c8cd4f8d576.webp

image-146-64c8cd50567b2.webp

image-147-64c8cd501e463.webp

image-148-64c8cd50b2c5c.webp

image-149-64c8cd50d627e.webp

BBC-Logo.webp

The-Independent-Logo.webp

Featured in

AI biomarkers, built for real-world impact and clinical trials. Meet us at ASCO 2026 | Booth #IH12.

Qure.ai Recognized Among TIME’s 100 Most Influential Companies of 2025

Qure.ai partners with Microsoft to increase access to its lung cancer detection and management suite in the U.S.

qTrack

The UK National Health Service (NHS) is currently piloting a groundbreaking artificial intelligence (AI) system that has the potential to revolutionize the way severe injuries are identified and treated in emergency settings. This cutting-edge technology, designed to quickly analyze CT scans, aims to expedite the diagnosis process and enable rapid treatment for patients with critical conditions.

The program, which is being developed by Qure.ai, a leading healthcare technology company, is currently undergoing rigorous testing at three prominent NHS trusts: Guys' and St Thomas', King's College Hospital Foundation, and the Northumbria Foundation. These pilot sites were carefully selected to assess the effectiveness and feasibility of implementing the AI system in real-world clinical settings.

At the heart of this innovative technology is a sophisticated algorithm that can rapidly analyze CT scans and identify severe injuries with remarkable accuracy. By leveraging advanced machine learning techniques and deep neural networks, the system can quickly flag cases that require immediate attention, alerting radiologists to prioritize their review and take swift action.

Pooja Rao, the co-founder of Qure.ai, emphasized the potential impact of this technology on patient outcomes. In cases of brain bleeding, for example, where every minute counts, the AI system could accelerate diagnosis by up to an hour during busy times. This significant reduction in the time taken to identify critical injuries can make a life-saving difference, enabling healthcare professionals to initiate appropriate treatment promptly.

The benefits of this AI-powered system extend beyond improving patient outcomes. By automating the initial analysis of CT scans, the technology can help alleviate the workload on radiologists, who often face a high volume of cases to review. This not only allows them to focus their expertise on the most critical cases but also reduces the risk of human error and ensures a more consistent and reliable diagnostic process.

The NHS recognizes the immense potential of this AI system and has ambitious plans for its future implementation. Following the successful completion of the pilot program, the NHS aims to extend the trial to an additional six to eight hospital trusts over the next two years. This expansion will provide valuable insights into the scalability and adaptability of the technology across different healthcare settings.

If the trials prove successful and the AI system demonstrates its effectiveness in improving patient outcomes and streamlining diagnostic processes, the NHS envisions a broader implementation across its network of hospitals. This would mark a significant milestone in the integration of AI in healthcare, setting a new standard for the early detection and treatment of severe injuries.

However, the implementation of such advanced technology also brings challenges that need to be addressed. Ensuring the accuracy and reliability of the AI system is of utmost importance, as any errors or false positives could have serious consequences for patient care. Rigorous validation and continuous monitoring will be essential to maintain the highest standards of performance and safety.

Furthermore, the integration of AI in healthcare requires a collaborative effort between technology developers, healthcare professionals, and policymakers. Training and education programs will be necessary to ensure that radiologists and other healthcare staff are equipped with the knowledge and skills to effectively utilize the AI system and interpret its results.

The NHS's pilot program of Qure.ai's AI system for identifying severe injuries in CT scans represents a significant step forward in the application of artificial intelligence in healthcare. By harnessing the power of advanced algorithms and machine learning, this technology has the potential to transform the way critical conditions are diagnosed and treated, ultimately saving lives and improving patient outcomes. As the NHS continues to explore and expand the use of AI in healthcare, it is clear that this innovative approach holds immense promise for the future of medical care in the UK and beyond.

thumbnail_I-News-logo.webp

I-News-logo.webp

NHS is piloting AI-assisted CT head scans that can quickly spot patients with serious injuries

<b>16th July 2021, Sydney</b>&nbsp;– Qure.ai leaders in developing deep learning algorithms for interpreting radiology images, is excited to announce a strategic partnership with Healthcare Imaging Services (HIS), the diagnostic imaging provider in the Healius Group.

The collaboration will see HIS integrating Qure’s artificial intelligence (AI) solutions to aid chest X-ray interpretation.

HIS has one of the largest networks of imaging centres in Australia and focuses on supplying high quality and comprehensive imaging diagnosis, annually processing close to three million scans. By using an automated X-ray screening technology called qXR from Qure, they will elevate patient care by aiding radiologists to prioritise critical cases, detect incidental findings and lower the chances of misdiagnosis.

The qXR AI algorithm can detect 30 distinct radiological abnormalities from chest X-rays, including lung opacities, nodules, cardiomegaly and pleural effusion. The first AI solution to be CE certified, qXR is now listed as a medical device on the Australian Register of Therapeutic Goods and has a sensitivity of over 95 per cent. Radiologists can use qXR as a pre-assistance read to separate normal from abnormal X-rays, making sure they get to the critical cases earlier.

Prashant Warier, CEO and co-founder of Qure.ai said, “Partnering with Healthcare Imaging Services is a significant milestone in making a positive contribution to Australia’s healthcare system. We are excited about how our AI technology for chest X-ray screening and interpretation can better the lives of both patients and medical personnel. Early disease detection has always been a critical factor in meticulous treatment, and better clinical outcomes for patients and our AI solution is geared to provide support to Australia’s doctors in both speed and accuracy of diagnoses.”

Dean Lewsam, CEO of Healthcare Imaging Services, is very excited about this collaboration: “This partnership is something as a business we are very excited about. We want to provide faster, more accurate care to our patients and the collaboration between our people across the country and qXR AI algorithm will allow us to do that.”

small_2-2.webp

thumbnail_2-2.webp

2-2.webp

Qure.ai partners with Healthcare Imaging Services to bring Artificial Intelligence to chest X-ray diagnosis in Australia

Seeking to address the urgent need for faster stroke and concussion diagnoses, <a href="https://www.businessinsider.in/tech/news/a-small-hospital-assam-is-using-ai-to-detect-strokes-in-tea-planters/articleshow/84194042.cms">Assam's Baptist Christian Hospital</a>, in the Tezpur town foothills of the Himalayas, has adopted Qure.ai's artificial intelligence solution for rapid brain CT scan analysis. 

The hospital predominantly serves tea plantation workers, a population heavily impacted by stroke—one of the significant causes of death in the region.

Qure.ai's AI-enabled solution, the qER, drastically reduces diagnosis time, providing potentially life-saving benefits. 

Rapid intervention is crucial, with strokes leading to millions of brain cell deaths per minute. 

Qure.ai co-founder Prashant Warrier said the qER could significantly speed up this process.

Dr. Jemin J Webster of Baptist Christian Hospital has praised the technology's efficiency, stating that the hospital has been diagnosing around 100 patients monthly since it implemented the technology in early 2021. 

Qure.ai anonymizes all data transferred to ensure users' privacy and continuously publishes its accuracy rate, regularly updating its technology.

Recognized globally for its ground-breaking AI solutions, Qure.ai has not only received certifications from the US FDA and Europe's CE but has also been validated by the World Health Organization for its tuberculosis diagnostic software.

small_Business-Insider-India-logo.webp

thumbnail_Business-Insider-India-logo.webp

Business-Insider-India-logo.webp

A small hospital in a remote corner of Assam is using AI to detect strokes in tea planters

Artificial intelligence (AI) is revolutionizing healthcare delivery in rural areas, as highlighted in a recent Financial Times podcast. The episode, hosted by John Thornhill, the Financial Times' innovation editor, explores the transformative impact of AI in diagnosing tuberculosis in a small Indian village. This insightful discussion sheds light on how AI technology, specifically developed by Qure.ai, is enhancing human perception and empowering doctors to make better-informed diagnoses, ultimately improving patient outcomes.

In the podcast, Madhumita Murgia, a journalist from the Financial Times, delves into the intricacies of how AI is being leveraged to bridge the gaps in healthcare delivery in remote areas. She shares her firsthand experience of witnessing the implementation of Qure.ai's AI technology in a rural setting, where access to advanced medical facilities and experienced healthcare professionals is often limited. By analyzing patient data and offering diagnostic assistance, AI is enabling doctors to identify and treat patients who might have otherwise been missed, thereby reducing the burden of undiagnosed and untreated diseases.

The episode features insightful interviews with two key figures in the field. Dr. Ashita Singh, the head of Medicine at Chinchpada Christian Hospital, provides a practitioner's perspective on how AI is transforming the way healthcare is delivered in rural areas. She highlights the challenges faced by healthcare professionals in resource-constrained settings and how AI-powered tools, like those developed by Qure.ai, are making a significant difference in their ability to accurately diagnose and treat patients.

Ziad Obermeyer, an associate professor at the University of California, Berkeley, offers an academic viewpoint on the potential of AI in healthcare. He explains how AI algorithms can analyze vast amounts of patient data, including medical images and electronic health records, to identify patterns and anomalies that might be difficult for human doctors to detect. By providing this additional layer of analysis and decision support, AI is augmenting the capabilities of healthcare professionals and improving the accuracy and efficiency of diagnoses.

The Financial Times podcast underscores the transformative potential of AI in addressing the healthcare disparities that exist between urban and rural areas. By bringing advanced diagnostic tools to underserved communities, AI is democratizing access to quality healthcare and ensuring that patients, regardless of their location, receive timely and accurate diagnoses. This is particularly crucial in the context of diseases like tuberculosis, which disproportionately affect vulnerable populations and require early detection and treatment to prevent the spread of infection.

The success stories shared in the podcast, such as the implementation of Qure.ai's AI technology in the small Indian village, serve as a testament to the power of AI in transforming rural healthcare. These examples demonstrate how AI can be effectively integrated into existing healthcare systems, complementing the expertise of healthcare professionals and improving patient outcomes. As more healthcare providers embrace AI-powered solutions, the potential for widespread impact on public health is immense.

The Financial Times podcast offers a compelling glimpse into the future of healthcare, where AI, like the technology developed by Qure.ai, is becoming a game-changer. By enhancing human perception, enabling early detection, and improving diagnostic accuracy, AI is poised to revolutionize the way healthcare is delivered in rural areas and beyond. As the adoption of AI in healthcare continues to grow, it holds the promise of reducing healthcare disparities, improving patient outcomes, and ultimately, saving lives.

large_Financial-Times-Logo.webp

medium_Financial-Times-Logo.webp

small_Financial-Times-Logo.webp

thumbnail_Financial-Times-Logo.webp

Financial-Times-Logo.webp

Can AI take healthcare where doctors don’t want to go?

Today, the UK Department of Health and Social Care announced that Qure.ai has been selected as one of the winners of the Artificial Intelligence in Health and Care Award, sponsored by the UK government. 

Qure.ai is a 5-year-old Sequoia-funded company builds Artificial Intelligence (AI) powered solutions to facilitate identification and treatment of stroke and head injuries. The Award has been instituted by the Accelerated Access Collaborative (AAC) in partnership with NHSX and the National Institute for Health Research (NIHR). T

he consortium is making £140 million available over four years in funding and support for promising AI technologies.

The award will drive Qure.ai’s mission to gather real-world evidence for its qER tool in an ER setting, in partnership with the NHS Guy’s and St. Thomas’ Foundation Trust, NHS King’s College Hospital Foundation Trust, NHS Northumbria Healthcare Foundation Trust and other key Major Trauma focused NHS trusts across the country.

qER is Qure.ai’s AI platform that identifies a range of critical markers on head CT scans, such as bleeds, strokes and fractures.

 The technology is CE-marked and received United States FDA clearance in 2020. qER will now be deployed in Accident and Emergency (A&amp;E) departments in the UK to improve diagnostic turn-around times for these critical conditions and help reduce missed diagnoses.

The NHS has seen a significant rise in A&amp;E footfalls as well as growing volumes and complexity of imaging, with CT and MRI volumes increasing by an average of 10% (over half a million scans) per year, while patient wait times in the A&amp;E have been steadily increasing too.

 For better patient outcomes, the time to diagnosis and treatment is critical, particularly for patients with neuro presentations such as head trauma or stroke.

Dr. Haris Shuaib, Consultant Physicist, Head of Clinical Scientific Computing at Guy’s and St Thomas’ NHS Foundation Trust said, “Our out-of-hours radiology reporting service would benefit greatly from an effective triaging and prioritisation system. With the qER system from Qure we hope to be able to manage critical findings like intracranial hemorrhage even more effectively.”

Dr Hugh Harvey, Managing Director, Hardian Health- “Winning a Phase 3 AAC award is a testimony to the strong consortium that has come together to support deployment and scaling of Qure’s market-leading qER software. 

Hardian Health is truly excited to be part of this fantastic consortium. We will be conducting cost-effectiveness analysis of the care pathways by involving all stakeholders, from NHS clinicians to patient advocacy groups”.

“We are excited about this Award from NHSX”, says Dr. Pooja Rao, R&amp;D Head and co-founder of Qure.ai. 

“This NHSX grant will help us demonstrate that appropriate use of AI technology leads to better patient outcomes and accrues economic benefits to the NHS system. It paves the way for wider adoption of Qure’s technology in the UK”.

small_3-1.webp

thumbnail_3-1.webp

3-1.webp

Qure.ai’s Brain CT AI wins funding from the NHS

&nbsp;India’s leading health-tech startup has collaborated with the international NGO PATH, to accelerate and intensify COVID-19 screening by making advanced AI diagnostic technology available to physicians across India through the Telegram App.​

Qure’s CE-certified AI solution can read and interpret chest X-ray to detect findings indicative of COVID-19 as well as quantify the proportion of lungs affected due to the lesions. The technology which is being used by the Mumbai Municipal corporation and super-specialty hospitals across the globe, is now available to physicians on the Telegram app.​

The second wave in India has led to a sharp scarcity of RT-PCR tests, as well as delayed reporting and lower accuracy in the test’s results. Qure’s AI solution can help as a preliminary screening mechanism. 

Chest X-rays are being increasingly preferred to assess and quantify the infection in the lungs as they are more easily available, inexpensive and inflict lower radiation levels. Qure’s AI bot would enable clinicians to triage for COVID-19 instantaneously. 

Physicians would only have to download the Qure bot from the Telegram app, upload the patient’s chest X-rays either as DICOMs images or as images taken by the smartphone camera. The result would be available in less than a minute and would serve as a second opinion or confirmation of diagnosis.​

PATH is an international NGO which has been on the forefront of enabling digital transformation in India. Working with various state governments, they have a strong history of improving the effectiveness of health programs in 22+ states through their network of physicians and healthcare workers.​

Prashant Warier, CEO and co-founder of Qure.ai said “What we’ve been seeing in the last few weeks is truly taking a toll on our frontline care givers and straining our public and private healthcare infrastructure severely. We need to implement and leverage technology that’s been extensively trained and validated to tackle this ongoing tragedy fast and it needs to be now.”​

Dr. Shibu Vijayan, Global TB Technical Director, PATH said “Qure’s technology detects ground-glass opacities and consolidation, which are indicative of COVID-19 infections. It quantifies affected lung volume and gives a COVID-19 score which will help physicians decide on the course of treatment. It will also help healthcare institutions with optimizing their resource allocation.”

small_6.webp

thumbnail_6.webp

6.webp

Qure.ai partners with the NGO PATH to accelerate and intensify COVID-19 screening

Fujifilm India Pvt. Ltd. is pleased to announce that FUJIFILM Corporation has introduced X-ray solutions augmented with qXR, Qure.ai’s computed aided radiology software application designed with deep-learning Artificial Intelligence (AI) technology. 

According to Qure.ai, the AI will analyze X-ray images to detect unconventional findings within seconds. Fujifilm’s portable X-ray FDR Xair system are equipped with a new image processing box called Expansion Unit EX-Mobile enabling to connect with qXR software. It will assist clinicians and technicians by flagging worrying markers at the point-of-care.

Qure’s peer-reviewed and proven chest X-ray interpretation technology, qXR can detect suspected markers indicative of COVID-19, tuberculosis, lung cancer, misplaced catheters and multiple other radiological findings allowing for further review and confirmatory testing. The technology has been extensively trained on a global dataset and can be used for both adult as well as pediatric images.

Another significant advancement is that the combination of EX-Mobile with Fujifilm’s portable X-ray FDR Xair systemwill bring the benefit of Qure’s AI technology not only to hospitals, but also regions which are geographically distant from the cities and emergency critical care. 

Furthermore, it will respond to the rapidly increasing global demand for support for effective lung procedures at medical sites, especially during the disease outbreaks.

“Fujifilm and Qure’s technology will deliver a support tool to assist the care providers for accurate diagnosis faster. 

With the help of Technology and special examination we can diagnose the disease while it is asymptomatic, with no signs or symptoms. The earlier detection of disease may lead to more cures or longer survival. 

Our partnership with Qure will support the expansion of Tuberculosis(TB) screening in India, and also other developing countries where there is limited access to such health service. We believe there’s tremendous potential in this partnership” said Koji Wada, General Manager, Fujifilm India Medical Division.”

“We are delighted to partner with Fujifilm to improve quality of care by accelerating patient triage, diagnostics and treatment. Qure.ai’s CE- certified and WHO endorsed technology will elevate patient care and reduce radiologists’ workload across healthcare institutions.” said Prashant Warier, CEO and Co-Founder, Qure.ai.

Fujifilm customers will be able to select one of the clinical packages available with qXR including:

Fujifilm and Qure aims provide high quality care in the increasingly dynamic and complex healthcare environment through future-proof AI technology.

small_4.webp

thumbnail_4.webp

4.webp

Fujifilm partners with Qure.ai to make intelligent X-ray solutions

Partnership between AstraZeneca’s Emerging Markets Health Innovation Hubs and Qure.ai demonstrates ongoing commitment to integrate innovative new technologies into the healthcare ecosystem of developing markets

AstraZeneca has announced a partnership, through its&nbsp;<a href="https://www.astrazeneca.com/partnering/partnering-case-studies/health-innovation-hubs-in-emerging-markets.html">Emerging Markets Health Innovation Hubs</a>&nbsp;programme, with&nbsp;<a href="https://qure.ai/">Qure.ai</a>&nbsp;(developers of deep learning algorithms for the interpretation of radiology images) to integrate innovative artificial intelligence (AI) solutions for the early detection of lung cancer in patients across AstraZeneca’s Emerging Markets region, covering Latin America (Argentina, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic and other Caribbean Islands, Ecuador, Guatemala, Honduras, Peru, Panama, Mexico, Nicaragua and Uruguay), Asia (Philippines, Malaysia and Thailand in 2020 and India, Indonesia and Vietnam in 2021) and the Middle East &amp; Africa (Gulf Cooperation Council countries).

Globally, chest X-rays are the most commonly ordered diagnostic imaging test, with millions of scans performed every year. 

Although chest X-rays are easily performed in primary care and referral settings, the interpretation of these X-rays requires significant skill and experience, and lack of expertise in reading the imaging can result in missed or delayed diagnosis.

A series of studies have described the use of deep learning algorithms to detect health markers, yielding promising results. ‘qXR’, Qure.ai’s chest X-ray interpretation tool, is able to automatically detect and localise up to 29 markers, including those indicative of possible lung cancer. 

There are several features of chest radiographs (such as sharply circumscribed nodules or masses, those with irregular margins, and those with ill-defined lesions) that can indicate the presence of lung cancer. 

The CE-marked qXR algorithm can not only detect lung cancer nodules with high levels of accuracy in under a minute, but also marks out the position and size of these nodules. It can aid clinicians in picking up minuscule nodules which may be missed even by experts. 

A study conducted by Qure.ai demonstrated a 17% improvement in sensitivity when using AI to interpret chest X-rays, compared to radiologist readings. Such aids in early detection can have considerable long-term benefits for medical professionals in their efforts to tackle lung cancer. It can also mean lower cost per-life-year saved.

The AstraZeneca and Qure.ai partnership aims to harness and scale-up the use of this technology to improve early-stage detection of lung cancer in the markets involved, to reduce mortality rates and improve patient outcomes. 

As part of the strategic collaboration, AstraZeneca’s Emerging Markets Health Innovation Hubs will work with Qure.ai to explore the application of deep learning algorithms to identify patients with suspicious radiographic lung markers and support their referral to arrive at a firm diagnosis. 

The collaboration will also focus on overcoming barriers that limit access to diagnostic tools to support early lung cancer detection.

The end goal of the partnership is to improve referral and diagnostic pathways for patients with possible lung cancers and increase lung cancer detection at an earlier stage – improving the patient journey and ultimately reducing lung cancer mortality rates around the world.

Leon Wang, AstraZeneca EVP International and Country President China, said “Improving long-term outcomes in lung cancer relies heavily on clinicians being able to identify patients in the early stages of the disease – giving them a better chance to provide curative-intent treatment. 

Qure.ai’s deep learning algorithm-based technology has the potential to provide clinicians with faster, more accurate diagnoses based on chest X-rays, helping secure those early-stage diagnoses and deliver better outcomes for patients. Innovations such as this are critical for boosting the capabilities of healthcare ecosystem, not just in Emerging Markets, but around the world, and this partnership supports our bold ambition of eliminating cancer as a cause of death.”

Prashant Warier, CEO and Co-Founder, Qure.ai, said “We are delighted to partner with AstraZeneca in the early detection of lung cancer using our AI solution for automated interpretation of chest X-rays. The software’s ability to process analogue and digital chest X-rays in a minute can help physicians in incidental diagnoses of lung cancer by pointing out small lung nodules which could have been missed in a cursory review. The solution also detects several other types of health markers from chest X-rays that are linked to infection, injuries and chronic diseases, and flags these to the physician, potentially creating other diagnostic pathways.”

small_5.jpg

thumbnail_5.jpg

5.jpg

AstraZeneca partners with Qure.ai to improve early stage diagnosis of lung cancer and reduce mortality rate in Latin America, Asia and Middle East & Africa regions

A clinical study evaluated Qure.ai algorithm’s ability to predict adverse clinical outcomes in patients with COVID-19

Health tech firm Qure.ai’s diagnostic tool for COVID-19 has been used as part of a clinical study conducted in Milan by IRCCS Ospedale San Raffaele. The study focused on the early predictors of clinical outcomes of COVID-19 and showed that the performance of Qure.ai’s chest X-ray interpretation technology, qXR, was comparable to radiologists’ assessment in predicting severity in initial chest x-rays in patients with COVID-19.

Published in&nbsp;European Radiology, the article stated that a high qXR chest X-ray quantitative score, based on percent of lung involvement, at admission was highly predictive of mortality due to COVID-19. This was comparable to what was obtained with the RALE score, previously validated to evaluate Acute Respiratory Distress Syndrome (ARDS).

IRCCS&nbsp;Ospedale San Raffaele&nbsp;has been using qXR technology since early April to aid the efforts of their physicians in pandemic management. qXR is one of Qure.ai’s AI-driven and machine-powered healthcare tools. It automatically generates chest X-ray interpretation reports and is faster and more efficient than humans in detecting, tuberculosis, chronic obstructive pulmonary diseases, lung malignancies and medical emergencies and in evaluating COVID-19 X-rays.

“As reported in our study, a qXR score ≥ 30 on chest x-rays at presentation is an independent predictor of of admission to intensive care unit (ICU) or deaths occurring before ICU admission in COVID-19 patients. These important findings of our study suggest that chest Xray and Artificial Intelligence may play a pivotal role in prognostic evaluation of COVID-19 disease” stated Professor Francesco De Cobelli, Head of Clinical and Experimental Radiology at IRCCS Ospedale San Raffaele.

Prashant Warier, CEO and co-founder of Qure.ai, said: “Our AI solution for chest X-rays qXR has proven to be useful in two areas in pandemic management. Firstly, to screen for individuals exhibiting signs of COVID-19 on a chest X-ray. Secondly, to monitor confirmed cases of COVID-19 to track the progression of the disease. Having deployed both these capabilities in hospitals and community screening programs across the globe, this study with Ospedale San Raffaele backs qXR’s ability to be an effective tool for predicting clinical outcomes at the first patient evaluation itself.”

small_9.webp

thumbnail_9.webp

9.webp

Qure.ai’s tech is as reliable as radiologists for COVID assessment

The role of artificial intelligence (AI) in radiology is ever-expanding, with new startups focusing on improving imaging diagnosis, particularly in stroke triage, as the incidence of stroke and neurovascular disease continues to surge globally. 

Pooja Rao, Ph.D., co-founder and head of research and development at <a href="http://qure.ai">Qure.ai</a>, states that while the industry is yet to rely on AI tools for diagnosis entirely, its use is accelerating in research and development, particularly in specialties like interventional radiology and neurosurgery.

Qure.ai's <a href="https://www.radiologytoday.net/archive/rtSO20p14.shtml">FDA 510(k) cleared tool</a>, qER, decreases the time to action by up to 97% by detecting critical markers in head CT scans and immediately alerting clinicians. 

Rao states that every bit of help AI tools can offer in this complex process directly improves patient outcomes and decreases the risk of death or permanent disability.

Furthermore, Greg Albers, MD, director of the Stanford Stroke Center, acknowledges the increasing influence of AI in medical practices and expects AI to be a significant part of the "new normal" post-pandemic. However, he emphasizes that AI's current role is to highlight potential issues for physicians rather than replace them.

small_3-2.webp

thumbnail_3-2.webp

3-2.webp

Quick Thinking- AI helps detect stroke and other neurovascular brain markers

The <a href="https://analyticsindiamag.com/how-deep-learning-is-used-for-tuberculosis-detection-in-city-of-nagpur/">global fight against Tuberculosis (TB)</a>, one of the world's most deadly infectious diseases, has found a strong ally in Artificial Intelligence (AI). 

In India, where the disease affects over 27 lakh lives yearly, <a href="http://qure.ai">Qure.ai</a>, a leading healthcare-focused AI firm, has stepped up to tackle this crisis in collaboration with PATH, a non-profit organization.

The initiative's primary target was the Maharashtra city of Nagpur, with 35% of its population suffering from TB. The region largely relies on informal healthcare providers who, while affordable and accessible, lack the necessary tools for early TB detection.

Enter qXR, Qure.ai's AI-powered chest X-ray interpretation platform. This revolutionary tool can accurately detect 29 different, clinically relevant lung markers, playing a vital role in identifying classic and atypical TB forms. It processes X-rays within minutes, swiftly identifying potential cases and alerting healthcare providers to expedite treatment procedures.

The tool's deep learning algorithms have been trained on a dataset of 3.6 million chest X-rays gathered from around 250 sites globally over four years. This AI-driven system can analyze multiple scans from the same patient sequentially, providing a progress report to track changes in lesions over time.

Dr. Shibu Vijayan, Global TB Technical Director at PATH, reported a 20% increase in the notification of TB cases since the implementation of qXR. 

With TB diagnosis drastically expedited, this system promises a promising future for rural healthcare providers seeking to tackle the rampant disease.

small_6-1.webp

thumbnail_6-1.webp

6-1.webp

How Deep Learning Is Used For Tuberculosis Detection In City Of Nagpur

<a href="http://qure.ai">Qure.ai</a> has joined the AI Connect Marketplace, offering state-of-the-art algorithms for enhanced diagnosis of pulmonary diseases and traumatic brain injuries (TBI) from X-rays and CT scans.

Qure.ai's algorithms have successfully transformed radiology functions in conventional hospital environments and have empowered remote healthcare teams with advanced medical imaging services. Already operational in 20 countries, Qure.ai has adapted its solutions to aid the global fight against COVID-19.

Key among Qure.ai's offerings is qXR, a CE-certified automated chest X-ray interpretation tool trained on over 3.5 million X-rays, and qER, an FDA Cleared and CE Certified head CT interpretation tool utilized by hospitals and teleradiology providers globally.

Now available on Wellbeing's AI Connect Marketplace, these solutions can be integrated into existing radiology workflows, thereby fast-tracking their adoption. Graeme Eccles, AI Partnership Director at Wellbeing, welcomes Qure.ai to the Marketplace, seeing its potential to help prioritize patient treatment, especially amidst the reported backlog of scans.

Qure.ai's CEO, Prashant Warier, anticipates their partnership with Wellbeing will help enrich healthcare systems, improve patient outcomes, and extend their reach across the UK's NHS.

small_4-1.webp

thumbnail_4-1.webp

4-1.webp

Qure Becomes Latest Vendor to join AI Connect Marketplace

Qure.ai today announced the appointment of Terri Bresenham to their advisory team. Terri will provide counsel and serve as a commercial advisor for Qure’s global market expansion. She brings with her 30 years of experience in the healthcare field and most recently served as the Chief Innovation Officer at GE Healthcare, leading transformation and growth.

“We’re delighted to have Terri on our team. She has led global businesses with exceptional success. Her experience in building new market models for sustainable healthcare will greatly benefit Qure as we expand our global operations,” said Prashant Warier, CEO and founder, Qure.ai.

“I am thrilled to join Qure’s advisory board, as we mutually share the passion of improving healthcare standards across the world. They are at an exciting time in their growth and I look forward to supporting their market expansion and positive impact to patient care.” commented Terri Bresenham.

Bresenham has led product development for medical devices, digital platforms and most recently clinical data science working with some of the most respected health systems across the world. She is a board member for several healthcare organizations, is active in community-based health projects, and is a champion for women leadership in technology and global health.

small_7.webp

thumbnail_7.webp

7.webp

Health-tech firm Qure.ai announces the appointment of Terri Bresenham to its board of advisors

Qure <a href="https://in.mashable.com/social-good/16430/ai-is-shaping-the-future-of-healthcare-heres-how">co-founders</a> Prashant Warier and Pooja Rao embarked on this journey in 2016, combining their expertise in deep learning, clinical knowledge, and scientific insights.

Qure.ai's prime offering is an automated chest X-ray interpretation technology that delivers precise readings in less than a minute. 

It can identify 28 different markers and detect tuberculosis, distinguish between typical and unconventional X-rays, and quantify the extent of lung infection. This innovative solution is now pivotal in the battle against the COVID-19 pandemic.

Another significant product by Qure.ai pertains to head CT scan interpretation. This AI algorithm, trained on thousands of X-rays and CT scans, pinpoints the brain's unconventionalities and gauges their severity.

The impact of AI in healthcare extends beyond Qure.ai, ranging from physical robots in hospitals to surgical aids, patient care, administrative tasks, and even drug discovery and vaccine development. With the AI health market projected to reach $6.6 billion by 2021, Qure.ai is riding this transformative technology's wave, helping redefine healthcare for a brighter future.

small_2-1.webp

thumbnail_2-1.webp

2-1.webp

AI is shaping the future of healthcare. Heres How.

<a href="http://qure.ai">Qure.ai</a> has been named among the world's 150 most promising digital health startups by US-based business analytics firm <a href="https://www.businessinsider.in/business/startups/news/oyo-announces-a-weekend-curfew-with-no-calls-and-slack-messages-and-surprise-holidays-for-its-employees/articleshow/77543069.cms">CB Insights</a>. 

The selection, which included another Indian company, Pharmeasy, came from an analysis of over 8,000 startups worldwide.

In a period where the digital health sector is gaining prime importance due to the ongoing COVID-19 pandemic, Qure.ai's recognition underscores the value of its AI-led solutions, specifically those facilitating quick medical tests and diagnostics. 

The startup recently made headlines for an AI solution identifying high-risk COVID-19 patients using chest X-rays and CT scans. This chest X-ray AI tool, qXR, is currently utilized in 28 countries.

Founded in 2016 by Dr. Pooja Rao and Prashant Warier, Qure.ai has recently raised approximately $16 million from Sequoia India and MassMutual Ventures Southeast Asia. 

This global recognition from CB Insights bodes well for Qure.ai, as India's health-tech industry is projected to reach $372 billion by 2022 and is expected to generate 40 million jobs by 2030, according to Invest India.

small_13-1.webp

thumbnail_13-1.webp

13-1.webp

These are the two Indian companies to feature in CB Insights 150 most promising digital health startups

In a <a href="https://www.embs.org/pulse/articles/ai-driven-covid-19-tools-to-interpret-quantify-lung-images/">concerted effort</a> to augment the fight against COVID-19, research groups across the globe are harnessing the power of artificial intelligence (AI) to revolutionize radiology. These efforts focus on developing tools that enable comprehensive quantitative analysis of lung images, particularly chest X-rays and computed tomography (CT) scans. 

The approach first noted in Wuhan, China, identifies shared health markers in lung images of COVID-19 patients, and employs AI to delineate the extent of lung involvement and to monitor patient progress.

Companies like <a href="http://qure.ai">Qure.ai</a> and Isometric are at the forefront of this technological leap. Qure.ai has developed AI algorithms that not only identify COVID-19 but also differentiate it from other respiratory illnesses. icometrix's AI-based technology, Young, has been pivotal in interpreting CT scans for signs of the disease.

Maryellen L. Giger, Ph.D., A.N. Pritzker Professor of Radiology at the University of Chicago, sees AI not as a replacement but as a tool to assist radiologists and clinicians in detecting and monitoring COVID-19 more quickly and objectively. These AI-based methods promise unprecedented detail and precision, invaluable in managing this global health crisis.

small_52.webp

thumbnail_52.webp

52.webp

AI-Driven COVID-19 Tools to Interpret, Quantify Lung Images

Qure.AI, led by Co-Founder and Head of Research and Development Dr. Pooja Rao, has developed AI-based software revolutionizing radiology analysis. 

Their innovations expedite the diagnosis and treatment process in neuroimaging cases, notably aiding in the timely treatment of ischemic stroke patients.

News and Press